Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ: MLTX )

55.70 +3.03 (+5.75%)
Streaming Delayed Price Updated: 1:28 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,127
Open 52.29
Bid (Size) 55.22 (6)
Ask (Size) 55.74 (1)
Prev. Close 52.67
Today's Range 52.29 - 55.84
52wk Range 37.55 - 64.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire

Performance

YTD
-6.47%
-6.47%
1 Month
+2.82%
+2.82%
3 Month
+9.62%
+9.62%
6 Month
+38.59%
+38.59%
1 Year
-9.49%
-9.49%

More News

Read More
MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024
Via InvestorPlace
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
From Komodo Health
Via Business Wire
Expert Ratings for MoonLake
Via Benzinga
Recap: MoonLake Q3 Earnings
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
Via Investor's Business Daily
16 Analysts Have This to Say About MoonLake
Via Benzinga
Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?
Via Benzinga
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Former Highflier MoonLake Plummeted 29% After A Recent Run
Via Investor's Business Daily
Dow Turns Lower; EchoStar Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Moves Higher; BioNTech Lowers 2023 Sales Outlook
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Arthritis-Focused MoonLake Immunotherapeutics Stock Trading Lower Today?
Via Benzinga
TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Rise; Nasdaq Gains 50 Points
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.